IFNG and immune system disorder: Later, a case report found that IFN-γ therapy combined with nivolumab (an anti-PD1 antibody) was effective in restoring immune function and eliminating invasive infection (162); and it was also being investigated in a phase 2 clinical trial to test whether rhIFN-γ would reverse the hypoinflammation and restoration of immune dysfunction of septic patients (163), and but no randomized, controlled trials have tested IFN-γ therapy in ICU patients to date.